Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE)-- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated ...
Lineage’s COR1 targets restoration of endothelial pump function via intracameral delivery and adhesion to Descemet membrane, ...
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
O'Connell projected, "We expect to read out ALTITUDE-AD late this year, inclusive of key clinical efficacy and safety measures." He indicated that results from this study would inform development ...
The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results